Pfizer Inc. $PFE Shares Purchased by Pzena Investment Management LLC

Pzena Investment Management LLC increased its holdings in shares of Pfizer Inc. (NYSE:PFE) by 0.6% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 5,958,922 shares of the biopharmaceutical company’s stock after purchasing an additional 34,030 shares during the period. Pzena Investment Management LLC’s holdings in Pfizer were worth $143,491,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently added to or reduced their stakes in the company. Godfrey Financial Associates Inc. purchased a new position in shares of Pfizer during the 4th quarter valued at about $26,000. Keb Asset Management LLC purchased a new stake in shares of Pfizer in the second quarter worth about $26,000. HFM Investment Advisors LLC boosted its stake in shares of Pfizer by 61.0% in the fourth quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company’s stock worth $28,000 after buying an additional 427 shares during the last quarter. Evolution Wealth Management Inc. grew its holdings in Pfizer by 132.2% during the first quarter. Evolution Wealth Management Inc. now owns 994 shares of the biopharmaceutical company’s stock worth $28,000 after acquiring an additional 566 shares during the period. Finally, Abound Financial LLC acquired a new stake in Pfizer during the fourth quarter worth about $31,000. 68.36% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on PFE. HSBC downgraded Pfizer from a “buy” rating to a “hold” rating and decreased their price target for the company from $32.00 to $28.00 in a report on Monday, July 6th. Guggenheim dropped their price objective on shares of Pfizer from $35.00 to $31.00 and set a “buy” rating on the stock in a research note on Friday, August 7th. UBS Group reaffirmed a “neutral” rating and set a $27.00 target price on shares of Pfizer in a report on Wednesday, May 27th. Citigroup boosted their target price on shares of Pfizer from $26.00 to $27.00 and gave the company a “neutral” rating in a research note on Wednesday, April 29th. Finally, Royal Bank Of Canada raised shares of Pfizer from an “underperform” rating to a “sector perform” rating and set a $25.00 price target on the stock in a report on Tuesday, June 9th. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, fourteen have issued a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $28.28.

Pfizer Stock Up 0.8%

NYSE PFE opened at $28.00 on Friday. The business has a fifty day moving average price of $25.30 and a 200 day moving average price of $26.25. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.96 and a current ratio of 1.27. The company has a market cap of $159.59 billion, a P/E ratio of 36.84 and a beta of 0.34. Pfizer Inc. has a one year low of $23.58 and a one year high of $28.75.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.68 by $0.09. Pfizer had a net margin of 6.80% and a return on equity of 19.63%. The company had revenue of $15.03 billion for the quarter, compared to analysts’ expectations of $14.40 billion. During the same quarter in the previous year, the company posted $0.78 EPS. The firm’s quarterly revenue was up 2.6% on a year-over-year basis. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Research analysts anticipate that Pfizer Inc. will post 2.98 EPS for the current fiscal year.

Pfizer Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Friday, July 24th will be given a dividend of $0.43 per share. The ex-dividend date is Friday, July 24th. This represents a $1.72 dividend on an annualized basis and a yield of 6.1%. Pfizer’s payout ratio is presently 226.32%.

Trending Headlines about Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer completed a Phase 1/2 study of PF-07868489, an experimental treatment for pulmonary arterial hypertension. The milestone supports early-stage pipeline progress, though additional clinical testing will be needed before any potential commercialization. Pfizer’s PF-07868489 PAH Study Reaches Completion
• Positive Sentiment: Several additional clinical updates highlighted progress across Pfizer’s development portfolio: completion of a Phase 1 atirmociclib study, completion of a drug-interaction study for PF-07248144, and a new Phase 1 liver study for atirmociclib. These milestones may reinforce confidence in Pfizer’s ability to replenish revenue as older products face competition. Atirmociclib Study Update PF-07248144 Study Update
• Positive Sentiment: Pfizer is also expanding real-world evidence efforts for prostate cancer therapies, Ibrance in advanced breast cancer, and a migraine treatment study in India. These studies could support broader use and strengthen commercial evidence for existing medicines. Pfizer Real-World Prostate Cancer Study
• Positive Sentiment: Investor-oriented coverage remains constructive, citing Pfizer’s roughly 19% year-to-date gain, attractive dividend yield, and reported hedge-fund buying. The stock’s move toward its 52-week high suggests improving sentiment. Hedge Funds Buying Pfizer
• Neutral Sentiment: Unusually large options activity may increase short-term trading interest, but it does not establish a clear fundamental direction for PFE. Pfizer Options Trading
• Negative Sentiment: Coverage of settlements involving thousands of Depo-Provera lawsuits raises concerns about potential legal costs and ongoing liability. Analysts also continue to weigh whether new drugs and acquisitions can offset revenue losses from expiring patents. Pfizer Legal Claims

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.